BMS-986393

DRUG2 trials

Sponsors

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Conditions

Multiple MyelomaRelapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

RecruitingNCT06121843

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyMultiple Myeloma

Start: 2024-02-22End: 2028-08-01Target: 147Updated: 2026-02-18

Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

RecruitingNCT06615479

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyRelapsed or Refractory Multiple Myeloma (RRMM)

Start: 2025-03-12End: 2032-06-22Target: 440Updated: 2026-03-17

Related Papers

Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)

Blood2025-11-03

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Blood2025-11-03

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Blood2025-11-03

QUINTESSENTIAL-2: A phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide.

Journal of Clinical Oncology2025-05-28